Hormonal Therapy Before Orchiopexy: A Unilateral Palpable Testis and Bilateral Nonpalpable Testes
Two boys with undescended testes sit on opposite sides of the AUA-versus-European guideline split: one with a straightforward unilateral, palpable testis, and one with bilateral, high, nonpalpable testes and a family who already asked about hormones before anyone raised it.
Desmond L., a fourteen-month-old boy, has a right undescended testis that has been palpable in the inguinal canal at every well-child visit since birth but has never migrated into the scrotum on its own. He is otherwise developing normally, and his parents — a chef and a retail manager both scheduling around unpredictable evening shifts — have already had to reschedule this referral twice around it, which has left them eager for whatever plan needs the fewest additional visits, not sentimental about which specific plan that is.
At fourteen months, spontaneous descent is no longer a realistic expectation — most descent that is going to happen does so in the first six months — and the AUA's 2014 cryptorchidism guideline recommends against hormonal therapy with hCG or GnRH to induce descent, citing response rates under 20% and a specific concern, drawn from Cortes and colleagues' 2000 study, that hormonal stimulation may actually harm germ cells in one-to-three-year-old boys who don't respond to it. Roughly half of testes undescended at birth complete their descent by three months of age, and further movement after six months is rare enough that guidelines treat that age as the point surgical referral should already be underway — part of why nobody in this conversation is proposing to simply keep watching a testis that has already had its best chance to arrive on its own. Desmond's testis is unilateral and already palpable, which places him about as far as this pivot gets from the population where any guideline entertains hormonal therapy at all — the debate that exists in this literature centers on bilateral, harder-to-reach testes, not a unilateral palpable one with a straightforward surgical target.
Where hormones don't earn a place
Straight to orchiopexy, no hormonal pretreatment. The AUA guideline is explicit here: hCG and GnRH produce testicular descent in fewer than one in five boys, there's no reliable long-term fertility benefit demonstrated for isolated hormonal therapy without surgery, and Cortes and colleagues found evidence of germ cell harm specifically in one-to-three-year-olds who don't respond. Desmond's testis is unilateral, palpable, and an easy surgical target — there's no version of this where hormones improve on a straightforward procedure.
I'd at least name the fertility-index literature before we close the door on hormones entirely — Schwentner and colleagues' 2005 randomized trial found neoadjuvant LHRH or hCG before orchiopexy improved the histologic fertility index measured on biopsy at the time of surgery, independent of whether descent happens on its own. That's a real, if narrower, endpoint than descent, and it's the reason some practices offer brief pretreatment even in straightforward unilateral cases.
That trial is real, and I won't pretend it doesn't exist — but it's a single study measuring a surrogate histologic marker, not a demonstrated improvement in actual adult fertility, and it sits right next to the OTHER finding in this literature: germ cell harm in non-responders his age.
Weighing a thin, surrogate-endpoint benefit against a documented harm signal, in a boy who doesn't need hormones to get his testis into the right place at all, is a worse trade here than in the bilateral, harder cases where hormones are actually earning their place in the conversation.
Desmond was scheduled for orchiopexy without hormonal pretreatment, at the family's preferred earliest date.
Not raised again after this visit, but worth recording: whether the fertility-index literature the endocrinologist cited should routinely come up in unilateral cryptorchidism consultations at all, given how quickly it was set aside here, or whether it's being appropriately reserved for the bilateral cases where the trade-off actually looks different.
Kai M.'s parents moved from Denmark eighteen months ago and specifically asked, at their first visit, whether hormonal treatment — something they understood to be more routinely offered at home — was an option here before any surgery is scheduled. He is eight months old, with bilateral undescended testes that have never been palpable on any examination, including under anesthesia at three months, when diagnostic laparoscopy located both testes intra-abdominally, roughly 2cm from the internal ring on each side.
Bilateral, high, nonpalpable testes are the population where the transatlantic guideline split is real rather than semantic: the AUA's 2014 guideline recommends against hormonal therapy across the board, citing the same low response rates and germ-cell-harm concern that applies to Desmond's case, while European and Nordic guidance has historically treated bilateral cryptorchidism, and bilateral hypogonadotropic hypogonadism specifically, as a scenario where gonadotropin-releasing hormone pretreatment may have a genuine fertility-preserving role — not by inducing descent, since these testes are far too high for that, but by correcting a hormonal deficit that bilateral high cryptorchidism itself often reflects. Hadziselimovic and colleagues' work on bilateral cryptorchidism has shown that roughly half of these boys have measurably abnormal mini-puberty, the hormonal surge that normally occurs in the first months of life and that Kai, born eight months ago, would have already been through — a window that, if defective, GnRH agonist treatment given now is intended to partially recreate rather than simply nudge a testis toward the scrotum. Intra-abdominal position 2cm from the internal ring on both sides also makes spontaneous descent essentially a non-factor in his case the way it still is, at least theoretically, for a lower-lying testis — whatever happens next for Kai will happen because a surgeon moves each testis deliberately, not because either one finishes a delayed migration on its own.
A question that turns on more than descent
For bilateral, high, nonpalpable testes, I'd offer a short GnRH agonist course before any surgery. This isn't the descent argument the AUA guideline is built to reject — it's a hormonal-deficit argument: roughly half of boys with bilateral cryptorchidism show defective mini-puberty, and a GnRH agonist given now can partially recreate that hormonal surge in a way that's been associated with better long-term spermatogonial counts in some European cohorts, independent of whether either testis ever descends on its own.
I take the mini-puberty mechanism seriously — it's more biologically specific than the general “try hormones first” framing AUA was really responding to. But the trials behind it are small, heterogeneous in dosing and endpoints, and haven't been independently replicated at a scale that changed the AUA panel's own read of the evidence, which still flags germ-cell harm in non-responders his age as a real, documented cost.
“More biologically plausible than the descent argument” is not the same claim as “proven to help,” and Kai's testes are getting surgically addressed either way — the actual question is whether we add an unlabeled hormonal exposure on top of that, not whether he gets treatment at all.
Then let the family make that specific trade with real information, since they already came in asking about it rather than needing it raised for them. I'd offer the GnRH course explicitly as an unlabeled, evidence-limited option aimed at fertility preservation rather than descent, name the germ-cell-harm data candidly, and proceed with staged laparoscopic orchiopexy regardless of what they choose — the surgery isn't contingent on the hormonal decision, and framing it that way keeps this from becoming a forced package deal.
Kai's family chose the GnRH agonist course after the informed discussion, with staged laparoscopic orchiopexy scheduled to proceed on its own timeline regardless of the hormonal response.
Not resolved, and not expected to be by this visit: whether a measurable improvement in germ cell counts, if later biopsy at the time of orchiopexy shows one, would justify recommending this course more broadly for bilateral high cryptorchidism at this center, or whether Kai's case will simply join the same small, heterogeneous literature it came from. The endocrinologist would treat a good result as worth tracking formally; the urologist remains skeptical that one more uncontrolled case moves the actual evidence base.